5/7
10:53 am
stok
Stoke Therapeutics, Inc. (NASDAQ: STOK) had its price target lowered by analysts at Canaccord Genuity Group Inc. from $21.00 to $20.00. They now have a "buy" rating on the stock.
Low
Report
Stoke Therapeutics, Inc. (NASDAQ: STOK) had its price target lowered by analysts at Canaccord Genuity Group Inc. from $21.00 to $20.00. They now have a "buy" rating on the stock.
5/7
08:17 am
stok
Stoke Therapeutics, Inc. (NASDAQ: STOK) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $35.00 price target on the stock.
Medium
Report
Stoke Therapeutics, Inc. (NASDAQ: STOK) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $35.00 price target on the stock.
5/6
10:37 am
stok
Stoke Therapeutics, Inc. (NASDAQ: STOK) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $22.00 price target on the stock.
Low
Report
Stoke Therapeutics, Inc. (NASDAQ: STOK) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $22.00 price target on the stock.
5/6
09:48 am
stok
Stoke Therapeutics, Inc. (STOK) Reports Q1 Loss, Tops Revenue Estimates [Yahoo! Finance]
Low
Report
Stoke Therapeutics, Inc. (STOK) Reports Q1 Loss, Tops Revenue Estimates [Yahoo! Finance]
5/6
07:26 am
stok
Stoke Therapeutics Reports First Quarter Financial Results and Provides Business Updates [Yahoo! Finance]
Medium
Report
Stoke Therapeutics Reports First Quarter Financial Results and Provides Business Updates [Yahoo! Finance]
5/6
07:00 am
stok
Stoke Therapeutics Reports First Quarter Financial Results and Provides Business Updates
Low
Report
Stoke Therapeutics Reports First Quarter Financial Results and Provides Business Updates
4/29
08:22 am
stok
Stoke Therapeutics Appoints Thomas Leggett as Chief Financial Officer [Yahoo! Finance]
Medium
Report
Stoke Therapeutics Appoints Thomas Leggett as Chief Financial Officer [Yahoo! Finance]
4/29
08:00 am
stok
Stoke Therapeutics Appoints Thomas Leggett as Chief Financial Officer
Medium
Report
Stoke Therapeutics Appoints Thomas Leggett as Chief Financial Officer
4/25
11:44 am
stok
Earnings Preview: Stoke Therapeutics, Inc. (STOK) Q1 Earnings Expected to Decline [Yahoo! Finance]
Medium
Report
Earnings Preview: Stoke Therapeutics, Inc. (STOK) Q1 Earnings Expected to Decline [Yahoo! Finance]
4/17
08:24 am
stok
Stoke Therapeutics Appoints Jason Hoitt as Chief Commercial Officer [Yahoo! Finance]
Medium
Report
Stoke Therapeutics Appoints Jason Hoitt as Chief Commercial Officer [Yahoo! Finance]
4/17
08:00 am
stok
Stoke Therapeutics Appoints Jason Hoitt as Chief Commercial Officer
Medium
Report
Stoke Therapeutics Appoints Jason Hoitt as Chief Commercial Officer
4/11
08:06 am
stok
Stoke Therapeutics, Inc. (NASDAQ: STOK) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $22.00 price target on the stock.
High
Report
Stoke Therapeutics, Inc. (NASDAQ: STOK) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $22.00 price target on the stock.
4/4
04:30 pm
stok
Stoke Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference
Low
Report
Stoke Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference
4/4
10:09 am
stok
Stoke Therapeutics, Inc. (NASDAQ: STOK) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.
Medium
Report
Stoke Therapeutics, Inc. (NASDAQ: STOK) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.
4/4
01:33 am
stok
Stoke Therapeutics: Positive Dravet Data Sends Shares Soaring, One For The Watchlist [Seeking Alpha]
Medium
Report
Stoke Therapeutics: Positive Dravet Data Sends Shares Soaring, One For The Watchlist [Seeking Alpha]
3/27
11:40 pm
stok
Stoke Therapeutics Announces Pricing of Upsized $125 Million Public Offering
Medium
Report
Stoke Therapeutics Announces Pricing of Upsized $125 Million Public Offering
3/27
10:16 am
stok
Stoke Therapeutics (STOK) Up on Upbeat Dravet Syndrome Study Data [Yahoo! Finance]
Medium
Report
Stoke Therapeutics (STOK) Up on Upbeat Dravet Syndrome Study Data [Yahoo! Finance]
3/26
04:07 pm
stok
Stoke Therapeutics Announces Proposed Public Offering
High
Report
Stoke Therapeutics Announces Proposed Public Offering
3/26
11:34 am
stok
Stoke Therapeutics' Anti-Epilepsy Drug Candidate Shows Substantial, Sustained Reductions In Seizure Frequency In Pretreated Patients [Yahoo! Finance]
Low
Report
Stoke Therapeutics' Anti-Epilepsy Drug Candidate Shows Substantial, Sustained Reductions In Seizure Frequency In Pretreated Patients [Yahoo! Finance]
3/26
10:44 am
stok
Stoke Therapeutics, Inc. (NASDAQ: STOK) had its price target raised by analysts at Wedbush from $13.00 to $17.00. They now have an "outperform" rating on the stock.
Medium
Report
Stoke Therapeutics, Inc. (NASDAQ: STOK) had its price target raised by analysts at Wedbush from $13.00 to $17.00. They now have an "outperform" rating on the stock.
3/26
08:13 am
stok
Stoke Therapeutics, Inc. (NASDAQ: STOK) had its price target raised by analysts at Needham & Company LLC from $14.00 to $22.00. They now have a "buy" rating on the stock.
High
Report
Stoke Therapeutics, Inc. (NASDAQ: STOK) had its price target raised by analysts at Needham & Company LLC from $14.00 to $22.00. They now have a "buy" rating on the stock.
3/26
08:13 am
stok
Stoke Therapeutics, Inc. (NASDAQ: STOK) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $35.00 price target on the stock.
High
Report
Stoke Therapeutics, Inc. (NASDAQ: STOK) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $35.00 price target on the stock.
3/26
08:13 am
stok
Stoke Therapeutics, Inc. (NASDAQ: STOK) was upgraded by analysts at TD Cowen from a "hold" rating to a "buy" rating.
High
Report
Stoke Therapeutics, Inc. (NASDAQ: STOK) was upgraded by analysts at TD Cowen from a "hold" rating to a "buy" rating.
3/26
08:12 am
stok
Stoke Therapeutics, Inc. (NASDAQ: STOK) had its price target raised by analysts at JPMorgan Chase & Co. from $6.00 to $13.00. They now have a "neutral" rating on the stock.
High
Report
Stoke Therapeutics, Inc. (NASDAQ: STOK) had its price target raised by analysts at JPMorgan Chase & Co. from $6.00 to $13.00. They now have a "neutral" rating on the stock.
3/26
08:11 am
stok
Stoke Therapeutics, Inc. (NASDAQ: STOK) had its price target raised by analysts at Canaccord Genuity Group Inc. from $18.00 to $21.00. They now have a "buy" rating on the stock.
High
Report
Stoke Therapeutics, Inc. (NASDAQ: STOK) had its price target raised by analysts at Canaccord Genuity Group Inc. from $18.00 to $21.00. They now have a "buy" rating on the stock.